X4 Pharmaceuticals, Inc — Investor Relations & Filings
Filings indexed
784
across all filing types
Latest filing
2026-05-12
Regulatory Filings
Country
US
United States of America
Listing
US
XFOR
X4 Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company that develops and commercializes therapies for rare diseases of the immune system. The company focuses on diseases resulting from the dysfunction of the CXCR4 pathway, a key signaling pathway for immune cell trafficking. Its lead product, XOLREMDI™ (mavorixafor), is an oral, selective antagonist of the CXCR4 receptor. It is approved for use in patients aged 12 and older with WHIM syndrome (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) to increase the number of circulating neutrophils and lymphocytes. The company's pipeline includes further investigation of mavorixafor for other chronic neutropenic disorders.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-05-12 | English | |
| S-3 - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-05-06 | English | |
| 10-Q - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-05-06 | English | |
| ARS - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-03-20 | English | |
| DEFA14A - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-03-20 | English | |
| DEF 14A - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-03-20 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 45339551 | 8-K - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-05-12 | English | ||
| 42006962 | S-3 - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-05-06 | English | ||
| 41806531 | 10-Q - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-05-06 | English | ||
| 32999251 | ARS - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-03-20 | English | ||
| 32999249 | DEFA14A - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-03-20 | English | ||
| 32999239 | DEF 14A - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-03-20 | English | ||
| 32963514 | 10-K - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-03-17 | English | ||
| 30181392 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 30181257 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 30181249 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 30181231 | SCHEDULE 13G Filing | 2026-02-17 | English | ||
| 30181103 | SCHEDULE 13G/A Filing | 2026-02-13 | English | ||
| 30181313 | SCHEDULE 13G/A Filing | 2026-02-05 | English | ||
| 30181211 | SCHEDULE 13G/A Filing | 2026-01-15 | English | ||
| 12390315 | FORM 4 | 2026-01-07 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Adaptimmune Therapeutics PLC
Commercial-stage biopharma developing TCR T-cell therapies …
|
ADAP | GB | Manufacturing |
|
Adaptogenics Health Corp.
Formulates and distributes functional mushroom and adaptoge…
|
ADPT | CA | Manufacturing |
|
Adastra Holdings
Manufacturer and supplier of ethnobotanical and processed c…
|
XTRX | CA | Manufacturing |
|
ADBIOTECH Co.,Ltd.
Develops IgY-based immune antibodies as alternatives to vac…
|
179530 | KR | Manufacturing |
|
ADC Therapeutics SA
Commercial-stage biotech developing antibody-drug conjugate…
|
ADCT | US | Manufacturing |
|
Addex Therapeutics Ltd.
Clinical-stage biopharma developing allosteric modulators f…
|
ADXN | CH | Manufacturing |
|
Adeshwar Meditex Limited
Manufacturer and exporter of medical disposables, surgical …
|
543309 | IN | Manufacturing |
|
ADIAL PHARMACEUTICALS, INC.
A clinical-stage biopharma developing genetically targeted …
|
ADIL | US | Manufacturing |
|
Adicet Bio, Inc.
Develops allogeneic gamma delta T cell therapies for cancer…
|
ACET | US | Manufacturing |
|
ADIM
Develops and manufactures human vaccines and biologics for …
|
4142 | TW | Manufacturing |
X4 Pharmaceuticals, Inc via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34355/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34355 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34355 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34355 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34355}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for X4 Pharmaceuticals, Inc (id: 34355)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.